Phaseline

Companies › Skyline Therapeutics (US)

Skyline Therapeutics (US): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SKG0106
Recombinant adeno-associated virus (AAV) vector-based in vivo gene therapy
–Phase 1Neovascular Age-related Macular DegenerationJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05986864SKG0106Phase 1Neovascular Age-related Macular DegenerationOphthalmologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.